Streetbeat News

Analyst Ratings

ALNY

RBC Capital analyst Luca Issi has reiterated an Outperform rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a price target of $235. This reaffirms the firm's positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 2:54 pm

WFG

RBC Capital analyst Matthew McKellar has reiterated an Outperform rating on West Fraser Timber (NYSE:WFG) and maintained a $97 price target.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 2:47 pm

GTE

RBC Capital analyst Luke Davis has maintained a 'Sector Perform' rating on Gran Tierra Energy, while lowering the price target from C$10 to C$9.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 2:45 pm

AXSM

Cantor Fitzgerald analyst Charles Duncan maintains an Overweight rating on Axsome Therapeutics (NASDAQ:AXSM) but lowers the price target from $108 to $103.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 2:38 pm

CRWD

PANW

CrowdStrike Holdings Inc (CRWD) shares fell in response to weak guidance from cybersecurity peer Palo Alto Networks Inc (PANW), which reported lower than expected future revenue and earnings forecasts. Palo Alto's soft guidance for Q3 and the full year 2024 led to a more than 25% drop in its shares, affecting the broader cybersecurity sector. CrowdStrike, which has not yet reported its Q4 earnings, saw its shares drop by 10.7%. Despite this, analysts remain optimistic about CRWD, with expectations of a significant rise in the stock price.

Portfolio Pulse from Adam Eckert

February 21, 2024 | 2:37 pm

SPT

Cantor Fitzgerald analyst Brett Knoblauch reiterated an Overweight rating on Sprout Social (NASDAQ:SPT) and maintained a $74 price target. This reaffirms the firm's positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 2:36 pm

VTYX

Traders are closely watching Ventyx Biosciences (VTYX) due to circulating unconfirmed analyst comments suggesting the company could be behind the next major weight loss drug. This speculation is based on a new publication indicating that NLRP3, a focus of Ventyx Biosciences, has shown significant weight loss effects similar to those of GLP-1.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 2:34 pm

PANW

Cantor Fitzgerald analyst Yi Fu Lee maintains an Overweight rating on Palo Alto Networks (NASDAQ:PANW) but lowers the price target from $400 to $350.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 2:34 pm

ENVX

Cantor Fitzgerald analyst Derek Soderberg has reiterated an Overweight rating on Enovix (NASDAQ:ENVX) and maintained a $30 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 2:30 pm

BRK-B

JPM

SLB

TM

On CNBC's 'Halftime Report Final Trades,' experts highlighted their top stock picks including Berkshire Hathaway (BRK-B, BRK-A), Schlumberger (SLB), Toyota Motor (TM), and JPMorgan Chase (JPM). Berkshire Hathaway received a price target increase from UBS, Schlumberger reiterated strong FY24 guidance, Toyota's small-car unit leaders resigned over misconduct, and JPMorgan's diversified portfolio was praised. The stocks showed varied price movements in the latest session.

Portfolio Pulse from Avi Kapoor

February 21, 2024 | 2:22 pm